Essential cookies by default. The browser ID, load-time metrics and error replays only run if you choose "Accept all".
We use essential cookies by default: sign-in, your choice in this banner (supstack-consent) and your language (NEXT_LOCALE). Vercel Web Analytics (cookieless page counts) and Sentry error reports (without replay) run either way. Only if you choose "Accept all" do we also create a browser ID in local storage (it ties your visits together in our site records), record error-replay diagnostics (Sentry: masked DOM snapshots, only when an error fires) and turn on load-time metrics (Vercel Speed Insights) so we can fix slow pages faster. Learn more about cookies
Dapsone (topical) doesn't have enough studies with structured effect-size data yet to pool a verdict. Browse the studies below for individual findings.
Most evidence is from high-quality meta-analyses and randomised trials published 2007–2026 with a typical study size of 3,010 participants.
Based on 17 studies · 2 meta-analyses · 6 RCTs · 44,697 total participants
Study base
17 studies indexed
By outcome
Every outcome below: Too few graded studies.
Skin healthTreatment success in roughly 40-69% over 12-16 weeks on the 5% gel, with inflammatory lesions responding more than comedones. Measurably better in women than men. Positioned as an alternative after first-line therapies rather than instead of them. · 2-12 weeks10 studies
10 studies
Anemia & hematology4 studies
4 studies
Safety profile3 studies
3 studies
Skin tone & pigmentation1 study
1 study
Active research area
11 studies in the last 5 years · Latest meta-analysis: 2026
200720162026
1Meta-Analysisn=22,645 · very large study2026
In plain English: Compared with placebo, only dapsone 5% [- 29.8 (95% confidence interval [CI] - 55.4 to - 4.1)] and erythromycin 2% [- 24.0 (95% CI - 45.7 to - 2.1)] significantly reduced inflammatory lesion counts.
Not stated in the abstract · Clin Drug Investig (2026)
32 studies comprising 34 randomised controlled trials, 22,645 patients, searched to October 2025.
Dapsone 5% was one of only TWO agents in the whole analysis to significantly reduce inflammatory lesion counts against placebo, at -29.8 (95% CI -55.4 to -4.1).
That confidence interval is very wide and its upper bound sits close to zero, so the estimate is significant but imprecise.
2RCTCited 69×n=3,010 · very large study2007
In plain English: Dapsone gel-treated patients achieved superior results in terms of the investigator's global acne assessment (P < .001) and the mean percentage reduction in inflammatory, noninflammatory, and total lesion counts (all, P < .001) at week 12.
Draelos ZD, et al. · J Am Acad Dermatol (2007)
Two identically designed 12-week randomised double-blind vehicle-controlled studies, 3,010 patients aged 12 and over, twice-daily monotherapy.
Reductions in inflammatory lesions favouring dapsone were apparent as early as 2 weeks and statistically significant by 4.
The abstract reports p values only and gives no absolute percentage reductions, so the size of the benefit cannot be read from it.
3Meta-AnalysisCited 10×n=11,424 · very large study2022
In plain English: Meta-analysis showed that dapsone gel alone or dapsone gel combined with isotretinoin was superior to excipient alone or oral isotretinoin alone in the treatment of acne (OR =1.51, 95% CI: 1.38-1.66, P<0.0001 random effects model, I2=0%).
Not stated in the abstract · Ann Palliat Med (2022)
7 trials, 11,424 participants, searched across seven databases including four Chinese-language ones.
Odds ratio 1.51 (95% CI 1.38 to 1.66) with I-squared of 0%, which is unusually consistent for a topical acne literature.
Dapsone was MORE effective in female patients: OR 1.80 (95% CI 1.46 to 2.23).
4RCTCited 10×n=4,327 · very large study2018
In plain English: Dapsone gel, 7.5% significantly reduced inflammatory, comedonal, and total lesions in skin phototypes I-III (P less than .001) and IV-VI (P less than equal to .01) versus vehicle.
Alexis AF, et al. · J Drugs Dermatol (2018)
Pooled data from two identically designed phase 3 randomised double-blind vehicle-controlled studies, once daily for 12 weeks, patients aged 12 and over with moderate acne.
2,216 patients with Fitzpatrick phototypes I-III and 2,111 with types IV-VI, so the darker-skin group was close to half the pooled population.
Significant improvement in both phototype subgroups on global assessment (both P < .0001) and on lesion counts.
5Systematic Review2024
In plain English: The administration of dapsone and heparin for the management of cutaneous loxoscelism demonstrated success in this case, with no sequelae observed.
Azuara-Antonio O, Isidoro Ortiz M, Jiménez-Oliver KD, Castillo-Cabrera M, Méndez-Salinas AK, Hernández-Ramírez L. · Sao Paulo medical journal = Revista paulista de medicina (2024)
Of the 22 patients, 12 (54.5%) were men.
The administration of dapsone and heparin for the management of cutaneous loxoscelism demonstrated success in this case, with no sequelae observed.
In general, the literature review indicated favorable outcomes in patients treated with antimicrobials and corticosteroids, with continuous healing of skin lesions.
In plain English: Dapsone monotherapy showed a treatment success rate of 40.1-69.4% for dapsone gel 5% and 29.8-47.0% for dapsone gel 7.5% when used for 12-16 weeks.
Not stated in the abstract · Int J Dermatol (2022)
14 studies, searched across PubMed, Embase and the Cochrane Library.
Treatment success 40.1-69.4% for the 5% gel and 29.8-47.0% for the 7.5% gel over 12-16 weeks.
The higher concentration shows the lower success range. The review notes variable treatment regimens make comparison across studies difficult, so this is not a like-for-like contrast.
7RCTCited 29×n=2,898 · very large study2012
In plain English: The mean reduction in total lesion counts in dapsone-treated females and males was, respectively, 46.6% vs 35.8% (P<.0001). … Significantly more dapsone-treated females than males achieved clinical success (48.6% vs 34.4%; P=.0003).
Tanghetti E, et al. · J Drugs Dermatol (2012)
POST-HOC pooled analysis of the two identical phase 3 vehicle-controlled trials (DAP0203 and DAP0204), 2,898 patients, US and Canada, 2002-2003. Sex was not randomised.
1,453 received dapsone (753 female, 700 male) and 1,445 received vehicle, assessed at weeks 2, 4, 6, 8 and 12.
REDUCTIONS in papulopustular and comedonal lesion counts were likewise significantly greater in female than male patients (each P < .0001).
8RCTCited 42×n=64 · small study2008
In plain English: After treatment with dapsone gel, 5%, no clinical or laboratory evidence of drug-induced hemolytic anemia was noted in G6PD-deficient subjects with acne vulgaris.
Piette WW, et al. · Arch Dermatol (2008)
Double-blind randomised vehicle-controlled CROSSOVER study in 64 patients aged 12 and over who had both G6PD deficiency and acne, with a 2-week washout between 12-week periods.
A 0.32 g/dL fall in haemoglobin occurred from baseline to 2 weeks on dapsone, was not accompanied by changes in reticulocytes, haptoglobin, bilirubin or lactate dehydrogenase, and was no longer apparent at 12 weeks.
The number of patients with a 1 g/dL drop was similar between treatments at both 2 and 12 weeks, and the largest single drop was in the VEHICLE group (1.7 g/dL against 1.5 g/dL on dapsone).
9Uses of dapsone in dermatologyReview2024
In plain English: Dapsone has been a valuable adjunctive therapy across various dermatologic conditions for years and evidence for its use continues to expand.
Lovell KK, Momin RI, Sangha HS, Feldman SR, Pichardo RO. · American journal of clinical dermatology (2024)
An overview of dapsone's pharmacokinetics, pharmacodynamics, indications, dosages, and safety profile are also reviewed.
Dapsone's versatility and safety profile make it a cost-effective treatment option in dermatology, particularly for patients with limited access to specialized medications.
Ongoing clinical trials are also described exploring dapsone's efficacy in novel dermatologic uses.
In plain English: The mean reduction from drugs and vehicles were 42 ± 7.1%, and 23 ± 5.0%, respectively; the mean contribution of vehicle toward drug effect was 55 ± 15% (range 35 - 82%).
Chiou WL · Int J Clin Pharmacol Ther (2012)
The most uncomfortable paper in this set, and it is about the whole topical acne category rather than dapsone alone.
Evaluated the vehicle's percentage contribution to reported efficacy for 8 commonly prescribed topical preparations at 10-12 weeks, 5% dapsone among them.
Drug arms averaged 42% total lesion reduction against 23% for vehicle arms, putting the vehicle's contribution at a mean 55% and a range of 35% to 82%.
11RCTCited 25×n=301 · medium study2010
In plain English: The authors did not detect a significant difference in the reduction of inflammatory lesions when dapsone was used in combination with adapalene gel or with benzoyl peroxide gel compared to the dapsone plus moisturizer combination group (P=0.052 for both versus moisturizer combination).
Fleischer AB, et al. · J Drugs Dermatol (2010)
301 patients aged 12 and over applied dapsone gel twice daily and were randomised 1:1:1 to adapalene, benzoyl peroxide or MOISTURISER once daily for 12 weeks.
Null on the main comparison: neither active partner significantly beat plain moisturiser for inflammatory lesion reduction (P = 0.052 for both).
The adapalene combination DID significantly beat the moisturiser combination on non-inflammatory and total lesion counts.
12Case Study2025
In plain English: Summarizing their features aims to improve diagnostic accuracy and management strategies, thus helping healthcare providers handle similar cases better.
In plain English: Dapsone appears to be associated with hemolytic anemia and the presence of schistocytes, suggesting mechanical intravascular haemolytic anaemia.
Archambeaud A, Aumont C, Pouplard C, Agier MS, Maillot F, Halimi JM, Bigot A. · PloS one (2026)
Amongst them, 10 (52.6%) had detectable schistocytes, ranging from 2 to 44/1000 erythrocytes (13 ± 14.2).
Dapsone appears to be associated with hemolytic anemia and the presence of schistocytes, suggesting mechanical intravascular haemolytic anaemia.
Whether Dapsone-associated biological thrombotic microangiopathy can be associated with target organ damage requires further investigation.
In plain English: Dapsone gel 7.5% was safe, well-tolerated, and efficacious in treating acne vulgaris and post-inflammatory hyperpigmentation in skin-of-color patients.
El-Kashlan N, Cices A, Kaufman B, Da Rosa JC, Sanabria-Gonzalez I, Khattri S, Alexis A. · Journal of drugs in dermatology : JDD (2024)
Dapsone gel, 7.5% applied daily for 24 weeks reduced acne severity, post-inflammatory hyperpigmentation, and decreased new inflammatory and noninflammatory acne lesions in skin of color patients with moderate to severe acne vulgaris.
Limitations: The sample size was small and underpowered to detect statistically significant changes in some endpoints.
Larger studies involving skin-of-color populations with acne vulgaris are warranted.
In plain English: The 7.5% topical formulation of dapsone is effective for papulopustular rosacea both on the first and second months of the treatment regardless of the age of the patient.
Özkoca D, Caf N. · Cutaneous and ocular toxicology (2024)
The decrease in the mean lesion count and IGA score of the patients in weeks 4 and 8 were statistically significant (p = 0.000 for all).
The 7.5% topical formulation of dapsone is effective for papulopustular rosacea both on the first and second months of the treatment regardless of the age of the patient.
Its safe side effect profile suits for a comfortable use in rosacea patients with a decreased skin tolerance.
In plain English: In conclusion, topical dapsone appears to have therapeutic advantages in several mucocutaneous conditions, especially in minimal, localized, and chronic eruptions.
Abtahi-Naeini B, Sattari H, Afshar K, Rastegarnasab F, Pourmahdi-Boroujeni M. · Journal of cosmetic dermatology (2025)
In conclusion, topical dapsone appears to have therapeutic advantages in several mucocutaneous conditions, especially in minimal, localized, and chronic eruptions.
In plain English: The therapeutic response between the studied groups was statistically significant in favor of the topical spironolactone group.
Not stated in the abstract · Arch Dermatol Res (2024)
28 patients with mild-to-moderate acne randomised to topical spironolactone 5% gel or topical dapsone 5% gel, twice daily for 12 weeks.
Dapsone came off worse. Response in the dapsone arm was poor in 50%, moderate in 42.9% and good in 7.1%, with none rated excellent. Spironolactone: poor 14.3%, moderate 28.6%, good 50%, excellent 7.1%.
Itching was significantly more common with dapsone; burning was the complaint with spironolactone.